ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1698

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses

Daniel Rios1, Nafeeza Hafeez1, Brian Desrosiers1, Shradha Rao1, Jess Floro1, Joelle Baddour1, Nisha Perez2, Greg Bisacchi2, Oliver Saunders2, Donna Romero1, Menachem Fromer2, Enrique Garcia-Rivera2, Wilson McKerrow2, Julie Behr2, Bryan Thornlow2, Dennis Zaller2, David Proia2 and Wenyan Miao2, 1Rome Therapeutics, Cambridge, MA, 2Rome Tx, Cambridge, MA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Autoinflammatory diseases, Epigenetics, immunology, Mouse Models, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs in the human genome have developed complex relationships with the host to regulate a variety of cellular functions.  TEs are largely silent in healthy adult cells but are reactivated and transcribed in certain disease states, such as cancer, autoimmunity, and neurodegeneration. Class I TEs are retrotransposons that have mobilized throughout the genome via reverse transcription of RNA intermediates. In humans, there are two Class I TEs that encode functional endogenous reverse transcriptase (RTs), LINE-1 and HERV-K. The DNA and RNA products from TE reactivation and reverse transcription are a potential source of nucleic acids that are recognized by pattern recognition receptors, such as cGAS, which trigger sterile proinflammatory responses. To understand the contribution of LINE-1 (L1) in the production of inflammatory products, we assessed the impact of genetic and chemical L1 perturbation in relevant disease models.

Methods: A rational and structure-guided campaign was initiated to identify nucleoside reverse transcriptase inhibitors (NRTI) for the reverse transcriptase function of L1. Compounds with nanomolar potency were screened for activity in blocking both L1 retrotransposition and a Type 1 interferon response in a cellular model of Aicardi-Goutières syndrome and a UV-keratinocyte model. Compounds with favorable pharmacology were profiled in an in vivo model of hypomethylation-induced Type 1 interferon production.

Results: RPT-A was identified as a potent and selective inhibitor of L1 RT. In enzymatic assays, its tri-phosphorylated form has an IC50 of 0.03 µM and 16 µM against L1 RT and HERV-K RT, respectively. RPT- A blocked 100% of LINE1 retrotransposition in a cell-based assay with an IC50 of 0.002 µM. To characterize the impact of RPT-A on Type 1 immune response, decitabine was used to induce L1 in TREX-1 knock out THP-1 cells carrying an IRF3-inducible luciferase reporter. L1 upregulation after decitabine challenge was confirmed and quantified using the L1EM algorithm. RPT-A effectively inhibited this response (IC50 = 0.55 µM). These observations were recapitulated in THP-1 reporter cells challenged with LPS. RPT-A was further interrogated in an in vitro UV challenge model. Immortalized human keratinocytes (HaCaT) were pre-treated with RPT-A for 72 hr and then exposed to sham or 0.1 mJ/cm2 UVB light. RPT-A blocked the UV-mediated Type 1 interferon response as measured by reduction in pTBK1 in whole cell lysate (IC50 = 327nM pTBK1). To translate these findings in vivo, mice were administered vehicle or RPT-A (1, 10, 100 mg/kg, PO) on days 1-5 and decitabine (10 mg/kg, PO) on days 2-5. RPT-A demonstrated a robust, dose-dependent inhibition of Type 1 IFN signaling in the kidney.

Conclusion: We identified a selective inhibitor of the L1 reverse transcriptase that potently inhibited a Type 1 interferon response in multiple in vitro and in vivo models. These results suggest that chemical inhibition of L1 RT may be a new therapeutic modality for Type 1 interferonopathies.


Disclosures: D. Rios, Rome Therapeutics, Pandion Therapeutics, Obsidian Therapeutics, Abata Therapeutics; N. Hafeez, None; B. Desrosiers, None; S. Rao, None; J. Floro, None; J. Baddour, None; N. Perez, None; G. Bisacchi, None; O. Saunders, None; D. Romero, ROME Therapeutics, Vincere Therapeutics, Centaurus Therapeutics; M. Fromer, ROME Therapeutics; E. Garcia-Rivera, None; W. McKerrow, None; J. Behr, None; B. Thornlow, None; D. Zaller, ROME Therapeutics, Ventus, Anokion, Merck/MSD, Bristol-Myers Squibb(BMS); D. Proia, None; W. Miao, None.

To cite this abstract in AMA style:

Rios D, Hafeez N, Desrosiers B, Rao S, Floro J, Baddour J, Perez N, Bisacchi G, Saunders O, Romero D, Fromer M, Garcia-Rivera E, McKerrow W, Behr J, Thornlow B, Zaller D, Proia D, Miao W. LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/line1-reverse-transcriptase-inhibitors-abrogate-type-1-interferon-responses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/line1-reverse-transcriptase-inhibitors-abrogate-type-1-interferon-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology